Ovarian cancer treatment strategies: focus on PARP inhibitors

Zimeng Li; Haoyong Li

doi:10.1117/12.2692606

7 September 2023 Ovarian cancer treatment strategies: focus on PARP inhibitors

Zimeng Li, Haoyong Li

Proceedings Volume 12789, International Conference on Modern Medicine and Global Health (ICMMGH 2023); 1278917 (2023) https://doi.org/10.1117/12.2692606
Event: International Conference on Modern Medicine and Global Health (ICMMGH 2023), 2023, Oxford, United Kingdom

Abstract

Ovarian cancer is a common gynecologic malignant tumor, and 70% of them are in the advanced stage of clinical therapy. The primary therapy for newly diagnosed ovarian carcinoma was tumor cell reduction combined with platinum-based chemotherapy. Although most patients achieve clinical remission following initiation of treatment, 70 percent of the patients have a relapse in 2-3 years, with a 5 years survival rate hovering at about 40 percent. More recently, poly- ADP ribose polymerase (ADP-ribose), PARP (PARP) inhibitors have become the first drugs that target DNA damage. PARP inhibitors are lethal by synthesizing DNA repair genes and have been approved for the treatment of BRCA mutations in ovarian and breast cancer. Through PARPDNA capture, PARP inhibitors destabilize the replication fork and cause cell death through replication stress. Inhibitors of poly (ADP-ribose) glycosylases (PARG) exploit and exacerbate cancer cells' replication defects. and can be used as a complement to PARP inhibitors that target various types of cancer. In this paper, I will describe the molecular mechanism of PARP inhibition, highlight the clinical features of the four PARP inhibitors, they discuss the predictive biomarkers of inhibitor susceptibility and resistance mechanism.

Citation Download Citation

Zimeng Li and Haoyong Li "Ovarian cancer treatment strategies: focus on PARP inhibitors", Proc. SPIE 12789, International Conference on Modern Medicine and Global Health (ICMMGH 2023), 1278917 (7 September 2023); https://doi.org/10.1117/12.2692606

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available